Intravitreal anti-VEGF agents such as aflibercept (Eylea®), ranibizumab (Lucentis®), bevacizumab (Avastin®) and increasingly faricimab (Vabysmo®) are commonly used in non-pregnant patients for the management of several chorioretinal diseases such as macular neovascularisation (MNV) (related to age-related macular degeneration (AMD), myopia, inflammatory chorioretinal diseases or other secondary causes), DMO, cystoid macular oedema related to retinal vein occlusion, and radiation maculopathy. This evidence concerns the gene VEGFA and chorioretinitis.